Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors (clinicaltrials.gov) - Sep 9, 2026 - P2 | N=46 | Recruiting | Sponsor: Emory University | Trial completion date: Nov 2027 ➔ Nov 2028 | Trial primary completion date: Nov 2026 ➔ Nov 2027
Checkpoint inhibition • Trial completion date • Trial primary completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • CD4
|